Zevra Therapeutics Inc.
$ 12.65
-2.47%
12 Jun - close price
- Market Cap 747,806,000 USD
- Current Price $ 12.65
- High / Low $ 13.74 / 12.63
- Stock P/E 6.29
- Book Value 3.48
- EPS 2.01
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 1.01 %
- 52 Week High 14.27
- 52 Week Low 7.16
About
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Analyst Target Price
$27.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-09 | 2025-11-05 | 2025-08-12 | 2025-05-13 | 2025-03-11 | 2024-11-12 | 2024-08-13 | 2024-05-08 | 2024-03-28 | 2023-11-07 | 2023-08-14 |
| Reported EPS | 0.6 | 0.19 | -0.01 | -0.06 | -0.06 | -0.69 | -0.69 | -0.48 | -0.4 | -0.4 | -0.4 | -0.15 |
| Estimated EPS | 0.08 | 0.05 | -0.02 | 1.38 | -0.18 | -0.3986 | -0.41 | -0.44 | -0.48 | -0.27 | -0.3 | -0.34 |
| Surprise | 0.52 | 0.14 | 0.01 | -1.44 | 0.12 | -0.2914 | -0.28 | -0.04 | 0.08 | -0.13 | -0.1 | 0.19 |
| Surprise Percentage | 650% | 280% | 50% | -104.3478% | 66.6667% | -73.1059% | -68.2927% | -9.0909% | 16.6667% | -48.1481% | -33.3333% | 55.8824% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZVRA
2026-06-12 00:09:32
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will continue as a consultant until December 31, 2026, to ensure a smooth transition while the company searches for a new CMO. CEO Neil F. McFarlane praised Dr. Quartel's contributions, including the FDA approval of MIPLYFFA and advancing other pipeline projects, affirming the company's readiness for future milestones.
2026-06-11 17:39:34
Canaccord Genuity has maintained a 'Buy' rating for Zevra Therapeutics Inc (ZVRA) with a price target of $29.00. GuruFocus's GF Value™ indicates the stock is 43.4% undervalued, and its GF Score™ of 69 suggests good potential for long-term returns, despite a low profitability rank. While insider selling has occurred, the analyst confidence and undervalued status present a compelling case for investors.
2026-06-11 12:39:34
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will continue as a consultant through December 31, 2026, to ensure a smooth transition while the company searches for a new CMO. Zevra highlighted Dr. Quartel's contributions to FDA approval of MIPLYFFA and progress on other pipeline programs, confirming it remains on track with regulatory milestones.
2026-06-11 12:39:34
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, will step down on July 3, 2026, for personal reasons but will continue as a consultant until December 31, 2026, during the search for a new CMO. The company reassures stakeholders that it remains on track with key regulatory milestones, including an EMA review for arimoclomol in Niemann-Pick disease type C and an ongoing Phase 3 trial for celiprolol in Vascular Ehlers-Danlos Syndrome, with further FDA discussions planned for late 2026. This transition occurs as Zevra focuses on advancing its pipeline and expanding its commercialization efforts.
2026-06-11 11:40:37
Zevra Therapeutics announced that its Chief Medical Officer, Adrian Quartel, M.D., will step down on July 3, 2026, due to personal reasons. Dr. Quartel will transition to a consulting role through December 31, 2026, as the company searches for a new CMO. The company acknowledged his contributions to FDA approval, commercial launch of MIPLYFFA, advances in celiprolol, and arimoclomol MAA submission, and confirmed it is on track with regulatory milestones and pipeline priorities.
2026-06-10 19:09:55
Maxim Group has maintained a 'Buy' rating for Zevra Therapeutics (ZVRA) and increased its price target from $25.00 to $35.00, suggesting a significant growth
